The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk ...

Procedures were performed under general anesthesia with systemic intravenous heparinization. Common femoral or radial artery access was obtained and guide catheters were placed into the parent artery, ...

A Prescription Drug User Fee Act target action date of June 13, 2025, has been set for the new drug application of ...

With approaches like high intensity focused ultrasound, patients with prostate cancer may experience lower rates of urinary ...

The NDA has been accepted for UGN-102 for intravesical solution for low-grade intermediate-risk non-muscle invasive bladder cancer.

US stocks look set to open mixed on Friday ahead of a relatively light day on the economic calendar. Housing starts data were released earlier in the morning, while the Baker Hughes rig count figures ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specia ...

Therefore, we believe that from the epidemiological point of view and considering the cost-benefit relation, we should focus on the subgroups at intermediate risk that have a reasonable number ... In ...

Expert Rev Cardiovasc Ther. 2012;10(4):433-439. This article suggests the need to reconsider the benefits of using aspirin in stroke prevention, especially in low-risk patients or patients not ...

Many states, including Texas and Oklahoma, do not allow execution witnesses to see the insertion of IVs or central venous catheters, carrying out the procedures in areas that are hidden from view. In ...